Durham-based HyperBranch Medical Technology Inc. has raised $1.7 million in equity funding to help take a new surgical sealant device through the regulatory approval process. The six participating ...

Stryker CorporationSYK recently announced the acquisition of HyperBranch Medical Technology for a deal value of $220 million in cash. The buyout is likely to boost Stryker's core Neurotechnology ...

Durham-based HyperBranch Medical Technology is one step closer in getting its new surgical sealant to market. The company announced it has completed patient enrollment in neurosurgery trials for ...

The FDA approved HyperBranch Medical Technology's Adherus AutoSpray Dural Sealant to provide watertight closure during cranial procedures, according to a March 30 approval letter. Approval came ...

HyperBranch is dedicated to developing medical devices based on its proprietary polymers and cross-linked hydrogels. Its Adherus AutoSpray Dural Sealant product is one of only two FDA-approved ...

DURHAM, N.C. — HyperBranch Medical Technology, Inc. announced today that on June 8, 2018, after a two-week trial in federal district court in Wilmington, Delaware, an 8-member jury found in favor of ...

Kalamazoo, Michigan - October 1, 2018 - Stryker (SYK) announced today the acquisition of privately-held HyperBranch Medical Technology, Inc. for a total equity value of approximately $220 million in ...

HyperBranch Medical of Durham, NC has won CE approval for its OcuSeal liquid ocular bandage, meaning it can be sold outside the U.S. OcuSeal is a liquid hydrogel polymer which becomes a ...

The new arrivals have advised clients such as Bessemer Venture Partners, HyperBranch and Mirror in a wide range of transactions and investments. Five partners in Cooley's Boston office ...

Adherus AutoSpray dural sealant. Manufactured and submitted by HyperBranch Medical Technology (Durham, NC). Adherus AutoSpray is designed for the controlled application of HyperBranch’s dural sealant.

Stryker Corporation SYK recently announced the acquisition of HyperBranch Medical Technology for a deal value of $220 million in cash. The buyout is likely to boost Stryker’s core ...